NCT07227207 A Study of TSRA-196 in Adults With PiZZ Alpha-1 Antitrypsin Deficiency (AATD)
| NCT ID | NCT07227207 |
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Sponsor | Tessera Therapeutics, Inc. |
| Condition | Alpha-1 Antitrypsin Deficiency (AATD) |
| Study Type | INTERVENTIONAL |
| Enrollment | 72 participants |
| Start Date | 2026-04-21 |
| Primary Completion | 2029-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 72 participants in total. It began in 2026-04-21 with a primary completion date of 2029-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a Phase 1/2, open-label, multi-center, dose escalation (Part 1), dose expansion (Part 2), and single repeat dose (Part 3) study to evaluate the safety, tolerability, efficacy, and PK/PD parameters of TSRA-196 in adults with the PiZZ genotype who have lung and/or liver disease associated with severe alpha-1 antitrypsin deficiency (AATD)
Eligibility Criteria
Inclusion Criteria: * Males or females who are 18 to 70 years of age, inclusive, at the time of signing the informed consent * Body mass index of 18 to 37 kg/m2, inclusive * Confirmed diagnosis of AATD and PiZZ genotype * At least one previous measure of blood total AAT level \<11 µmol/L * Nonsmoker for at least 6 months before screening and must remain nonsmoking for the entire study duration * Either AAT treatment-naïve or washed out of all investigational or approved treatments that modify AAT levels for 5 half-lives or at least 4 weeks, whichever is longer, before TSRA-196 administration Parts 1A and 2A (AATD lung disease with no or minimal liver fibrosis) * Clinically significant lung disease, defined as 1) evidence of emphysema or bronchiectasis by computed tomography or 2) DLCO \<70% of the predicted value or 3) ppFEV1 \<80% * ppFEV1 ≥35% * METAVIR fibrosis score F0 or F1 confirmed by liver biopsy at screening, or a liver stiffness measure by FibroScan ≤7 kPa at screening * FIB-4 index score ≤3.25 at screening * ALT and/or AST \<ULN at screening Parts 1B and 2B (AATD liver disease with significant or severe liver fibrosis, with or without AATD lung disease) * METAVIR fibrosis score F2 or F3 confirmed by liver biopsy at screening. A liver biopsy conducted within 12 months before screening is acceptable as a substitute. * Liver stiffness measure by FibroScan \>7 and ≤15 kPa at screening * ALT and/or AST \<2 x ULN at screening Exclusion Criteria: * Presence of genetic variation in SERPINA1 gene that may disrupt the function of TSRA-196, determined by screening genotyping * History of liver disease unrelated to AATD, or history of or clinical signs of cirrhosis * Significant lung disease not attributable to manifestations of AATD, as determined by the investigator * History of one or more hospitalizations due to severe exacerbation of underlying lung disease during the year before screening or received IV antibiotics for treatment of a pulmonary infection within 6 months before screening * Unstable AATD-related COPD, as determined by the investigator, or severe bronchiectasis * Lung volume reduction surgery within 1 year before screening or plan to receive lung volume reduction surgery during the study period * Documented chronic need for positive airway pressure therapy beyond nocturnal use * Seropositive for human immunodeficiency virus (HIV) (HIV-1 or HIV-2) * Seropositive for hepatitis B (hepatitis B surface antigen \[HBsAg\] or hepatitis B core antibody \[HBcAb\] positive) with detectable HBV DNA * Hepatitis C virus (HCV) RNA positive at screening (Parts 1A and 2A), or HCV RNA positive and/or HCV antibody positive at screening (Parts 1B and 2B) * Has received an organ transplant or is on a waiting list for an organ transplant * Prior treatment with gene therapy using viral vectors or intended to permanently change the patient's DNA * Any investigational products within 30 days before dosing or plan to take an investigational product before the end of study
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07227207 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Alpha-1 Antitrypsin Deficiency (AATD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07227207 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07227207 currently recruiting?
Yes, NCT07227207 is actively recruiting participants. Contact the research team at clinicalinfo@tesseratx.com for enrollment information.
Where is the NCT07227207 trial being conducted?
This trial is being conducted at Jacksonville, United States, Boston, United States, Rochester, United States, Charleston, United States and 6 additional locations.
Who is sponsoring the NCT07227207 clinical trial?
NCT07227207 is sponsored by Tessera Therapeutics, Inc.. The trial plans to enroll 72 participants.